Last reviewed · How we verify
Ciclosporin and Mycophenolate-mofetil
This combination suppresses T-cell activation and proliferation through calcineurin inhibition (ciclosporin) and inosine monophosphate dehydrogenase inhibition (mycophenolate mofetil) to prevent organ rejection.
This combination suppresses T-cell activation and proliferation through calcineurin inhibition (ciclosporin) and inosine monophosphate dehydrogenase inhibition (mycophenolate mofetil) to prevent organ rejection. Used for Organ transplant rejection prevention, Autoimmune disease management.
At a glance
| Generic name | Ciclosporin and Mycophenolate-mofetil |
|---|---|
| Sponsor | University of Giessen |
| Drug class | Immunosuppressant combination |
| Target | Calcineurin (ciclosporin); IMPDH type II (mycophenolate mofetil) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Ciclosporin binds calcineurin and blocks IL-2 production and T-cell activation, while mycophenolate mofetil selectively inhibits IMPDH type II in T and B lymphocytes, reducing their proliferation. Together, they provide synergistic immunosuppression for transplant rejection prevention and autoimmune disease management.
Approved indications
- Organ transplant rejection prevention
- Autoimmune disease management
Common side effects
- Nephrotoxicity
- Hypertension
- Gastrointestinal disturbances
- Infections
- Tremor
- Gingival hyperplasia
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (PHASE2)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciclosporin and Mycophenolate-mofetil CI brief — competitive landscape report
- Ciclosporin and Mycophenolate-mofetil updates RSS · CI watch RSS
- University of Giessen portfolio CI